Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis.

Bethel MA, Patel RA, Merrill P, Lokhnygina Y, Buse JB, Mentz RJ, Pagidipati NJ, Chan JC, Gustavson SM, Iqbal N, Maggioni AP, Öhman P and 5 more

Show all authors

Poulter NR, Ramachandran A, Zinman B, Hernandez AF, Holman RR

The lancet. Diabetes & endocrinology6 Dec 2017Cited by 476 (Europe PMC)

PMID29221659DOI10.1016/s2213-8587(17)30412-6PepBankPUB-29221659

Source link PubMedAsk about this study

Jump to 22 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study22

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone22

In this study, the peptide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking the peptide.

01HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In adults with type 2 diabetes, pooled GLP-1 receptor agonists (lixisenatide, liraglutide, semaglutide, extended-release exenatide) reduced three-point MACE by 10% versus placebo.
In plain wordsIn adults with type 2 diabetes, the GLP-1 drug class as a group lowered major heart events by 10% compared with placebo.
Peptide
Liraglutide
Outcome
DecreaseThree-point MACE
Study
n: not reported in source
Comparator
Placebo
Outcome group
Cardiovascular events · Cardiovascular
Source sentences
Summary
Compared with placebo, GLP-1 receptor agonist treatment showed a significant 10% relative risk reduction in the three-point major adverse cardiovascular event primary outcome (cardiovascular mortality, non-fatal myocardial infarction, and non-fatal stroke; HR 0·90, 95% CI 0·82-0·99; p=0·033
1 context sentence(design, population, supporting numbers)
Summary · context
In this systematic review and meta-analysis, we analysed data from eligible trials that assessed the safety and efficacy of GLP-1 receptor agonists compared with placebo in adult patients (aged 18 years or older) with type 2 diabetes and had a primary outcome including, but not limited to, cardiovas…
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-2922165901
02HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome
In adults with type 2 diabetes, pooled GLP-1 receptor agonists (lixisenatide, liraglutide, semaglutide, extended-release exenatide) reduced three-point MACE by 10% versus placebo.
In plain wordsIn adults with type 2 diabetes, the GLP-1 drug class as a group lowered major heart events by 10% compared with placebo.
Peptide
Semaglutide
Outcome
DecreaseThree-point MACE
Study
n: not reported in source
Comparator
Placebo
Outcome group
Cardiovascular events · Cardiovascular
Source sentences
Summary
Compared with placebo, GLP-1 receptor agonist treatment showed a significant 10% relative risk reduction in the three-point major adverse cardiovascular event primary outcome (cardiovascular mortality, non-fatal myocardial infarction, and non-fatal stroke; HR 0·90, 95% CI 0·82-0·99; p=0·033
1 context sentence(design, population, supporting numbers)
Summary · context
In this systematic review and meta-analysis, we analysed data from eligible trials that assessed the safety and efficacy of GLP-1 receptor agonists compared with placebo in adult patients (aged 18 years or older) with type 2 diabetes and had a primary outcome including, but not limited to, cardiovas…
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-2922165902
03HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In adults with type 2 diabetes, pooled GLP-1 receptor agonists (lixisenatide, liraglutide, semaglutide, extended-release exenatide) reduced cardiovascular mortality by 13% versus placebo.
In plain wordsIn adults with type 2 diabetes, the GLP-1 drug class as a group lowered deaths from heart causes by 13% compared with placebo.
Peptide
Liraglutide
Outcome
DecreaseCardiovascular mortality
Study
n: not reported in source
Comparator
Placebo
Outcome group
Mortality · Cardiovascular
Source sentences
Summary
a 13% RRR in cardiovascular mortality (0·87, 0·79-0·96; p=0·007
1 context sentence(design, population, supporting numbers)
Summary · context
In this systematic review and meta-analysis, we analysed data from eligible trials that assessed the safety and efficacy of GLP-1 receptor agonists compared with placebo in adult patients (aged 18 years or older) with type 2 diabetes and had a primary outcome including, but not limited to, cardiovas…
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-2922165903
04HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome
In adults with type 2 diabetes, pooled GLP-1 receptor agonists (lixisenatide, liraglutide, semaglutide, extended-release exenatide) reduced cardiovascular mortality by 13% versus placebo.
In plain wordsIn adults with type 2 diabetes, the GLP-1 drug class as a group lowered deaths from heart causes by 13% compared with placebo.
Peptide
Semaglutide
Outcome
DecreaseCardiovascular mortality
Study
n: not reported in source
Comparator
Placebo
Outcome group
Mortality · Cardiovascular
Source sentences
Summary
a 13% RRR in cardiovascular mortality (0·87, 0·79-0·96; p=0·007
1 context sentence(design, population, supporting numbers)
Summary · context
In this systematic review and meta-analysis, we analysed data from eligible trials that assessed the safety and efficacy of GLP-1 receptor agonists compared with placebo in adult patients (aged 18 years or older) with type 2 diabetes and had a primary outcome including, but not limited to, cardiovas…
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-2922165904
05HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In adults with type 2 diabetes, pooled GLP-1 receptor agonists (lixisenatide, liraglutide, semaglutide, extended-release exenatide) reduced all-cause mortality by 12% versus placebo.
In plain wordsIn adults with type 2 diabetes, the GLP-1 drug class as a group lowered deaths from any cause by 12% compared with placebo.
Peptide
Liraglutide
Outcome
DecreaseAll-cause mortality
Study
n: not reported in source
Comparator
Placebo
Outcome group
Mortality · Whole body
Source sentences
Summary
a 12% relative risk reduction in all-cause mortality (0·88, 0·81-0·95; p=0·002
1 context sentence(design, population, supporting numbers)
Summary · context
In this systematic review and meta-analysis, we analysed data from eligible trials that assessed the safety and efficacy of GLP-1 receptor agonists compared with placebo in adult patients (aged 18 years or older) with type 2 diabetes and had a primary outcome including, but not limited to, cardiovas…
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-2922165905
06HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome
In adults with type 2 diabetes, pooled GLP-1 receptor agonists (lixisenatide, liraglutide, semaglutide, extended-release exenatide) reduced all-cause mortality by 12% versus placebo.
In plain wordsIn adults with type 2 diabetes, the GLP-1 drug class as a group lowered deaths from any cause by 12% compared with placebo.
Peptide
Semaglutide
Outcome
DecreaseAll-cause mortality
Study
n: not reported in source
Comparator
Placebo
Outcome group
Mortality · Whole body
Source sentences
Summary
a 12% relative risk reduction in all-cause mortality (0·88, 0·81-0·95; p=0·002
1 context sentence(design, population, supporting numbers)
Summary · context
In this systematic review and meta-analysis, we analysed data from eligible trials that assessed the safety and efficacy of GLP-1 receptor agonists compared with placebo in adult patients (aged 18 years or older) with type 2 diabetes and had a primary outcome including, but not limited to, cardiovas…
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-2922165906
07HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In adults with type 2 diabetes, pooled GLP-1 receptor agonists had no significant effect on fatal and non-fatal myocardial infarction versus placebo.
In plain wordsIn adults with type 2 diabetes, the GLP-1 drug class as a group did not significantly change heart attacks compared with placebo.
Peptide
Liraglutide
Outcome
No significant changeFatal and non-fatal myocardial infarction
Study
n: not reported in source
Comparator
Placebo
Outcome group
Cardiovascular events · Cardiovascular
Source sentences
Summary
No significant effect of GLP-1 receptor agonists was identified on fatal and non-fatal myocardial infarction, fatal and non-fatal stroke, hospital admission for unstable angina, or hospital admission for heart failure.
1 context sentence(design, population, supporting numbers)
Summary · context
In this systematic review and meta-analysis, we analysed data from eligible trials that assessed the safety and efficacy of GLP-1 receptor agonists compared with placebo in adult patients (aged 18 years or older) with type 2 diabetes and had a primary outcome including, but not limited to, cardiovas…
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-2922165907
08HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome
In adults with type 2 diabetes, pooled GLP-1 receptor agonists had no significant effect on fatal and non-fatal myocardial infarction versus placebo.
In plain wordsIn adults with type 2 diabetes, the GLP-1 drug class as a group did not significantly change heart attacks compared with placebo.
Peptide
Semaglutide
Outcome
No significant changeFatal and non-fatal myocardial infarction
Study
n: not reported in source
Comparator
Placebo
Outcome group
Cardiovascular events · Cardiovascular
Source sentences
Summary
No significant effect of GLP-1 receptor agonists was identified on fatal and non-fatal myocardial infarction, fatal and non-fatal stroke, hospital admission for unstable angina, or hospital admission for heart failure.
1 context sentence(design, population, supporting numbers)
Summary · context
In this systematic review and meta-analysis, we analysed data from eligible trials that assessed the safety and efficacy of GLP-1 receptor agonists compared with placebo in adult patients (aged 18 years or older) with type 2 diabetes and had a primary outcome including, but not limited to, cardiovas…
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-2922165908
09HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In adults with type 2 diabetes, pooled GLP-1 receptor agonists had no significant effect on fatal and non-fatal stroke versus placebo.
In plain wordsIn adults with type 2 diabetes, the GLP-1 drug class as a group did not significantly change strokes compared with placebo.
Peptide
Liraglutide
Outcome
No significant changeFatal and non-fatal stroke
Study
n: not reported in source
Comparator
Placebo
Outcome group
Cardiovascular events · Cardiovascular
Source sentences
Summary
No significant effect of GLP-1 receptor agonists was identified on fatal and non-fatal myocardial infarction, fatal and non-fatal stroke, hospital admission for unstable angina, or hospital admission for heart failure.
1 context sentence(design, population, supporting numbers)
Summary · context
In this systematic review and meta-analysis, we analysed data from eligible trials that assessed the safety and efficacy of GLP-1 receptor agonists compared with placebo in adult patients (aged 18 years or older) with type 2 diabetes and had a primary outcome including, but not limited to, cardiovas…
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-2922165909
10HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome
In adults with type 2 diabetes, pooled GLP-1 receptor agonists had no significant effect on fatal and non-fatal stroke versus placebo.
In plain wordsIn adults with type 2 diabetes, the GLP-1 drug class as a group did not significantly change strokes compared with placebo.
Peptide
Semaglutide
Outcome
No significant changeFatal and non-fatal stroke
Study
n: not reported in source
Comparator
Placebo
Outcome group
Cardiovascular events · Cardiovascular
Source sentences
Summary
No significant effect of GLP-1 receptor agonists was identified on fatal and non-fatal myocardial infarction, fatal and non-fatal stroke, hospital admission for unstable angina, or hospital admission for heart failure.
1 context sentence(design, population, supporting numbers)
Summary · context
In this systematic review and meta-analysis, we analysed data from eligible trials that assessed the safety and efficacy of GLP-1 receptor agonists compared with placebo in adult patients (aged 18 years or older) with type 2 diabetes and had a primary outcome including, but not limited to, cardiovas…
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-2922165910
11HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In adults with type 2 diabetes, pooled GLP-1 receptor agonists had no significant effect on hospital admission for unstable angina versus placebo.
In plain wordsIn adults with type 2 diabetes, the GLP-1 drug class as a group did not significantly change hospital stays for unstable angina compared with placebo.
Peptide
Liraglutide
Outcome
No significant changeHospital admission for unstable angina
Study
n: not reported in source
Comparator
Placebo
Outcome group
Cardiovascular events · Cardiovascular
Source sentences
Summary
No significant effect of GLP-1 receptor agonists was identified on fatal and non-fatal myocardial infarction, fatal and non-fatal stroke, hospital admission for unstable angina, or hospital admission for heart failure.
1 context sentence(design, population, supporting numbers)
Summary · context
In this systematic review and meta-analysis, we analysed data from eligible trials that assessed the safety and efficacy of GLP-1 receptor agonists compared with placebo in adult patients (aged 18 years or older) with type 2 diabetes and had a primary outcome including, but not limited to, cardiovas…
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-2922165911
12HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome
In adults with type 2 diabetes, pooled GLP-1 receptor agonists had no significant effect on hospital admission for unstable angina versus placebo.
In plain wordsIn adults with type 2 diabetes, the GLP-1 drug class as a group did not significantly change hospital stays for unstable angina compared with placebo.
Peptide
Semaglutide
Outcome
No significant changeHospital admission for unstable angina
Study
n: not reported in source
Comparator
Placebo
Outcome group
Cardiovascular events · Cardiovascular
Source sentences
Summary
No significant effect of GLP-1 receptor agonists was identified on fatal and non-fatal myocardial infarction, fatal and non-fatal stroke, hospital admission for unstable angina, or hospital admission for heart failure.
1 context sentence(design, population, supporting numbers)
Summary · context
In this systematic review and meta-analysis, we analysed data from eligible trials that assessed the safety and efficacy of GLP-1 receptor agonists compared with placebo in adult patients (aged 18 years or older) with type 2 diabetes and had a primary outcome including, but not limited to, cardiovas…
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-2922165912
13HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In adults with type 2 diabetes, pooled GLP-1 receptor agonists had no significant effect on hospital admission for heart failure versus placebo.
In plain wordsIn adults with type 2 diabetes, the GLP-1 drug class as a group did not significantly change hospital stays for heart failure compared with placebo.
Peptide
Liraglutide
Outcome
No significant changeHospital admission for heart failure
Study
n: not reported in source
Comparator
Placebo
Outcome group
Cardiovascular events · Cardiovascular
Source sentences
Summary
No significant effect of GLP-1 receptor agonists was identified on fatal and non-fatal myocardial infarction, fatal and non-fatal stroke, hospital admission for unstable angina, or hospital admission for heart failure.
1 context sentence(design, population, supporting numbers)
Summary · context
In this systematic review and meta-analysis, we analysed data from eligible trials that assessed the safety and efficacy of GLP-1 receptor agonists compared with placebo in adult patients (aged 18 years or older) with type 2 diabetes and had a primary outcome including, but not limited to, cardiovas…
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-2922165913
14HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome
In adults with type 2 diabetes, pooled GLP-1 receptor agonists had no significant effect on hospital admission for heart failure versus placebo.
In plain wordsIn adults with type 2 diabetes, the GLP-1 drug class as a group did not significantly change hospital stays for heart failure compared with placebo.
Peptide
Semaglutide
Outcome
No significant changeHospital admission for heart failure
Study
n: not reported in source
Comparator
Placebo
Outcome group
Cardiovascular events · Cardiovascular
Source sentences
Summary
No significant effect of GLP-1 receptor agonists was identified on fatal and non-fatal myocardial infarction, fatal and non-fatal stroke, hospital admission for unstable angina, or hospital admission for heart failure.
1 context sentence(design, population, supporting numbers)
Summary · context
In this systematic review and meta-analysis, we analysed data from eligible trials that assessed the safety and efficacy of GLP-1 receptor agonists compared with placebo in adult patients (aged 18 years or older) with type 2 diabetes and had a primary outcome including, but not limited to, cardiovas…
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-2922165914
15HumanNot a test of Liraglutide aloneSystematic reviewSafety outcome
In adults with type 2 diabetes, pooled GLP-1 receptor agonists did not differ from placebo in severe hypoglycaemia.
In plain wordsIn adults with type 2 diabetes, the GLP-1 drug class as a group did not differ from placebo in severe low blood sugar.
Peptide
Liraglutide
Outcome
No significant changeSevere hypoglycaemia
Study
n: not reported in source
Comparator
Placebo
Outcome group
Adverse events · Metabolic and weight
Source sentences
Summary
Overall, no significant differences were seen in severe hypoglycaemia, pancreatitis, pancreatic cancer, or medullary thyroid cancer reported between GLP-1 receptor agonist treatment and placebo.
1 context sentence(design, population, supporting numbers)
Summary · context
In this systematic review and meta-analysis, we analysed data from eligible trials that assessed the safety and efficacy of GLP-1 receptor agonists compared with placebo in adult patients (aged 18 years or older) with type 2 diabetes and had a primary outcome including, but not limited to, cardiovas…
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-2922165915
16HumanNot a test of Semaglutide aloneSystematic reviewSafety outcome
In adults with type 2 diabetes, pooled GLP-1 receptor agonists did not differ from placebo in severe hypoglycaemia.
In plain wordsIn adults with type 2 diabetes, the GLP-1 drug class as a group did not differ from placebo in severe low blood sugar.
Peptide
Semaglutide
Outcome
No significant changeSevere hypoglycaemia
Study
n: not reported in source
Comparator
Placebo
Outcome group
Adverse events · Metabolic and weight
Source sentences
Summary
Overall, no significant differences were seen in severe hypoglycaemia, pancreatitis, pancreatic cancer, or medullary thyroid cancer reported between GLP-1 receptor agonist treatment and placebo.
1 context sentence(design, population, supporting numbers)
Summary · context
In this systematic review and meta-analysis, we analysed data from eligible trials that assessed the safety and efficacy of GLP-1 receptor agonists compared with placebo in adult patients (aged 18 years or older) with type 2 diabetes and had a primary outcome including, but not limited to, cardiovas…
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-2922165916
17HumanNot a test of Liraglutide aloneSystematic reviewSafety outcome
In adults with type 2 diabetes, pooled GLP-1 receptor agonists did not differ from placebo in pancreatitis.
In plain wordsIn adults with type 2 diabetes, the GLP-1 drug class as a group did not differ from placebo in pancreatitis.
Peptide
Liraglutide
Outcome
No significant changePancreatitis
Study
n: not reported in source
Comparator
Placebo
Outcome group
Adverse events · Gastrointestinal
Source sentences
Summary
Overall, no significant differences were seen in severe hypoglycaemia, pancreatitis, pancreatic cancer, or medullary thyroid cancer reported between GLP-1 receptor agonist treatment and placebo.
1 context sentence(design, population, supporting numbers)
Summary · context
In this systematic review and meta-analysis, we analysed data from eligible trials that assessed the safety and efficacy of GLP-1 receptor agonists compared with placebo in adult patients (aged 18 years or older) with type 2 diabetes and had a primary outcome including, but not limited to, cardiovas…
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-2922165917
18HumanNot a test of Semaglutide aloneSystematic reviewSafety outcome
In adults with type 2 diabetes, pooled GLP-1 receptor agonists did not differ from placebo in pancreatitis.
In plain wordsIn adults with type 2 diabetes, the GLP-1 drug class as a group did not differ from placebo in pancreatitis.
Peptide
Semaglutide
Outcome
No significant changePancreatitis
Study
n: not reported in source
Comparator
Placebo
Outcome group
Adverse events · Gastrointestinal
Source sentences
Summary
Overall, no significant differences were seen in severe hypoglycaemia, pancreatitis, pancreatic cancer, or medullary thyroid cancer reported between GLP-1 receptor agonist treatment and placebo.
1 context sentence(design, population, supporting numbers)
Summary · context
In this systematic review and meta-analysis, we analysed data from eligible trials that assessed the safety and efficacy of GLP-1 receptor agonists compared with placebo in adult patients (aged 18 years or older) with type 2 diabetes and had a primary outcome including, but not limited to, cardiovas…
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-2922165918
19HumanNot a test of Liraglutide aloneSystematic reviewSafety outcome
In adults with type 2 diabetes, pooled GLP-1 receptor agonists did not differ from placebo in pancreatic cancer.
In plain wordsIn adults with type 2 diabetes, the GLP-1 drug class as a group did not differ from placebo in pancreatic cancer.
Peptide
Liraglutide
Outcome
No significant changePancreatic cancer
Study
n: not reported in source
Comparator
Placebo
Outcome group
Adverse events · Cancer
Source sentences
Summary
Overall, no significant differences were seen in severe hypoglycaemia, pancreatitis, pancreatic cancer, or medullary thyroid cancer reported between GLP-1 receptor agonist treatment and placebo.
1 context sentence(design, population, supporting numbers)
Summary · context
In this systematic review and meta-analysis, we analysed data from eligible trials that assessed the safety and efficacy of GLP-1 receptor agonists compared with placebo in adult patients (aged 18 years or older) with type 2 diabetes and had a primary outcome including, but not limited to, cardiovas…
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-2922165919
20HumanNot a test of Semaglutide aloneSystematic reviewSafety outcome
In adults with type 2 diabetes, pooled GLP-1 receptor agonists did not differ from placebo in pancreatic cancer.
In plain wordsIn adults with type 2 diabetes, the GLP-1 drug class as a group did not differ from placebo in pancreatic cancer.
Peptide
Semaglutide
Outcome
No significant changePancreatic cancer
Study
n: not reported in source
Comparator
Placebo
Outcome group
Adverse events · Cancer
Source sentences
Summary
Overall, no significant differences were seen in severe hypoglycaemia, pancreatitis, pancreatic cancer, or medullary thyroid cancer reported between GLP-1 receptor agonist treatment and placebo.
1 context sentence(design, population, supporting numbers)
Summary · context
In this systematic review and meta-analysis, we analysed data from eligible trials that assessed the safety and efficacy of GLP-1 receptor agonists compared with placebo in adult patients (aged 18 years or older) with type 2 diabetes and had a primary outcome including, but not limited to, cardiovas…
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-2922165920
21HumanNot a test of Liraglutide aloneSystematic reviewSafety outcome
In adults with type 2 diabetes, pooled GLP-1 receptor agonists did not differ from placebo in medullary thyroid cancer.
In plain wordsIn adults with type 2 diabetes, the GLP-1 drug class as a group did not differ from placebo in medullary thyroid cancer.
Peptide
Liraglutide
Outcome
No significant changeMedullary thyroid cancer
Study
n: not reported in source
Comparator
Placebo
Outcome group
Adverse events · Cancer
Source sentences
Summary
Overall, no significant differences were seen in severe hypoglycaemia, pancreatitis, pancreatic cancer, or medullary thyroid cancer reported between GLP-1 receptor agonist treatment and placebo.
1 context sentence(design, population, supporting numbers)
Summary · context
In this systematic review and meta-analysis, we analysed data from eligible trials that assessed the safety and efficacy of GLP-1 receptor agonists compared with placebo in adult patients (aged 18 years or older) with type 2 diabetes and had a primary outcome including, but not limited to, cardiovas…
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-2922165921
22HumanNot a test of Semaglutide aloneSystematic reviewSafety outcome
In adults with type 2 diabetes, pooled GLP-1 receptor agonists did not differ from placebo in medullary thyroid cancer.
In plain wordsIn adults with type 2 diabetes, the GLP-1 drug class as a group did not differ from placebo in medullary thyroid cancer.
Peptide
Semaglutide
Outcome
No significant changeMedullary thyroid cancer
Study
n: not reported in source
Comparator
Placebo
Outcome group
Adverse events · Cancer
Source sentences
Summary
Overall, no significant differences were seen in severe hypoglycaemia, pancreatitis, pancreatic cancer, or medullary thyroid cancer reported between GLP-1 receptor agonist treatment and placebo.
1 context sentence(design, population, supporting numbers)
Summary · context
In this systematic review and meta-analysis, we analysed data from eligible trials that assessed the safety and efficacy of GLP-1 receptor agonists compared with placebo in adult patients (aged 18 years or older) with type 2 diabetes and had a primary outcome including, but not limited to, cardiovas…
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-2922165922

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · source ClinicalTrials.gov (opens in a new tab)

Status unknownPhase not statedNCT03959865

GLP-1 REceptor Agonists and Real World EvIdeNce

University of Padovan = 6,00019 Dec 2018 to est. 31 May 2019

Type 2 Diabetes

Trial page ClinicalTrials.govUpdated 22 May 2019

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 3Current
12 Oct 2026, 12:10 UTC
Study results updated
Version 2
9 Oct 2026, 03:06 UTC
Study data updated · source update from Europe PMC
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC